brain tumor glioblastoma
Conditions
Interventions
Supramarginal resection will be guided by ADC/FET. To make sure that the
standard treatment is always guaranteed, T1c MRI abnormalities will be included
in the surgical target.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age >= 18 years - New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma - Indication for a surgical resection and adjuvant treatment according to the neuro oncology multidisciplinary meeting - Eligible for a supramarginal resection according to two neurosurgeons in consensus - Karnofsky Performance Score (KPS) >= 70
Exclusion criteria
Exclusion criteria: - Previous brain surgery or cranial radiotherapy - Significant other brain pathology, in the opinion of the PI or designee, such as multiple sclerosis, neurodegenerative disease, stroke - Tumor located infratentorially or in the spinal cord - Lack of adequate social or family support needed for adherence to the further postoperative therapeutic regimen - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is the optimization of ADC/FET-guided resection. Volumetric and percentual extent of resection, as measured with MRI and PET imaging, combined with surgery-induced morbidity will be used as outcome parameters. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameters will be the histopathology-based diagnostic accuracy of APT-CEST MRI in comparison with FET PET, cognitive performance over time and progression free survival. | — |
Countries
Netherlands
Outcome results
None listed